CA3044771A1 - Crystalline forms of a janus kinase inhibitor - Google Patents
Crystalline forms of a janus kinase inhibitor Download PDFInfo
- Publication number
- CA3044771A1 CA3044771A1 CA3044771A CA3044771A CA3044771A1 CA 3044771 A1 CA3044771 A1 CA 3044771A1 CA 3044771 A CA3044771 A CA 3044771A CA 3044771 A CA3044771 A CA 3044771A CA 3044771 A1 CA3044771 A1 CA 3044771A1
- Authority
- CA
- Canada
- Prior art keywords
- crystalline form
- composition
- crystalline
- beta
- peak
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437262P | 2016-12-21 | 2016-12-21 | |
| US62/437,262 | 2016-12-21 | ||
| PCT/JP2017/045731 WO2018117153A1 (en) | 2016-12-21 | 2017-12-20 | Crystalline forms of a janus kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3044771A1 true CA3044771A1 (en) | 2018-06-28 |
Family
ID=60991475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3044771A Pending CA3044771A1 (en) | 2016-12-21 | 2017-12-20 | Crystalline forms of a janus kinase inhibitor |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11339181B2 (enExample) |
| EP (1) | EP3559003B1 (enExample) |
| JP (3) | JP2020502224A (enExample) |
| KR (1) | KR102788829B1 (enExample) |
| CN (2) | CN110325536A (enExample) |
| AU (1) | AU2017380213B2 (enExample) |
| BR (1) | BR112019012210A2 (enExample) |
| CA (1) | CA3044771A1 (enExample) |
| ES (1) | ES2926986T3 (enExample) |
| IL (1) | IL267393B2 (enExample) |
| MX (1) | MX386181B (enExample) |
| TW (1) | TWI822666B (enExample) |
| WO (1) | WO2018117153A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3560932T3 (pl) | 2016-12-21 | 2026-06-29 | Japan Tobacco Inc. | Sposób wytwarzania pochodnych 7H‑pirolo[2,3‑d]pirymidyny i ich syntetycznych produktów pośrednich |
| JP7597714B2 (ja) * | 2019-08-07 | 2024-12-10 | ロート製薬株式会社 | 涙液分泌促進用眼科組成物 |
| CN111606929B (zh) * | 2020-06-30 | 2023-07-07 | 中瀚(齐河县)生物医药科技有限公司 | 德高替尼的制备方法 |
| CA3210150A1 (en) * | 2021-02-02 | 2022-08-11 | Pfizer Inc. | Dosing regime for treatment of chronic hand eczema |
| JP7807247B2 (ja) * | 2021-02-05 | 2026-01-27 | ロート製薬株式会社 | シェーグレン症候群治療剤 |
| KR20240027044A (ko) * | 2021-07-30 | 2024-02-29 | 일라이 릴리 앤드 캄파니 | 바리시티닙을 사용한 손 습진의 치료 |
| AU2024229918A1 (en) * | 2023-02-28 | 2025-09-18 | Assia Chemical Industries Ltd. | Solid state forms of delgocitinib and process thereof |
| WO2024225445A1 (en) * | 2023-04-27 | 2024-10-31 | Japan Tobacco Inc. | Crystalline form of delgocitinib |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009500666A (ja) * | 2005-07-07 | 2009-01-08 | トムソン ライセンシング | 対応スタンドを備えたフラット画面ディスプレイシステム |
| EP2108641A1 (en) * | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
| BRPI1012108B8 (pt) * | 2009-05-22 | 2021-05-25 | Incyte Corp | composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico |
| TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| GB201004200D0 (en) * | 2010-03-15 | 2010-04-28 | Univ Basel | Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
| US20140343034A1 (en) * | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
| WO2015060208A1 (ja) * | 2013-10-21 | 2015-04-30 | 日本たばこ産業株式会社 | 眼疾患の治療剤又は予防剤 |
| BR112017026173A2 (pt) * | 2015-07-07 | 2018-08-14 | Japan Tobacco, Inc. | Método para produção de derivado de 7h-pirrolo [2,3-d]pirimidina e intermediário do mesmo |
-
2017
- 2017-12-20 TW TW106144831A patent/TWI822666B/zh active
- 2017-12-20 BR BR112019012210-9A patent/BR112019012210A2/pt not_active Application Discontinuation
- 2017-12-20 CN CN201780086980.3A patent/CN110325536A/zh active Pending
- 2017-12-20 CA CA3044771A patent/CA3044771A1/en active Pending
- 2017-12-20 MX MX2019007462A patent/MX386181B/es unknown
- 2017-12-20 AU AU2017380213A patent/AU2017380213B2/en active Active
- 2017-12-20 ES ES17829724T patent/ES2926986T3/es active Active
- 2017-12-20 JP JP2019533666A patent/JP2020502224A/ja active Pending
- 2017-12-20 US US16/470,854 patent/US11339181B2/en active Active
- 2017-12-20 WO PCT/JP2017/045731 patent/WO2018117153A1/en not_active Ceased
- 2017-12-20 CN CN202511159370.4A patent/CN121045220A/zh active Pending
- 2017-12-20 EP EP17829724.8A patent/EP3559003B1/en active Active
- 2017-12-20 KR KR1020197017128A patent/KR102788829B1/ko active Active
-
2019
- 2019-06-16 IL IL267393A patent/IL267393B2/en unknown
-
2022
- 2022-12-26 JP JP2022207814A patent/JP2023024729A/ja active Pending
-
2024
- 2024-08-13 JP JP2024134769A patent/JP2024161449A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN121045220A (zh) | 2025-12-02 |
| US20200017527A1 (en) | 2020-01-16 |
| BR112019012210A2 (pt) | 2019-11-12 |
| KR20190092440A (ko) | 2019-08-07 |
| CN110325536A (zh) | 2019-10-11 |
| JP2023024729A (ja) | 2023-02-16 |
| MX2019007462A (es) | 2019-08-29 |
| EP3559003B1 (en) | 2022-08-24 |
| JP2024161449A (ja) | 2024-11-19 |
| AU2017380213B2 (en) | 2022-01-06 |
| RU2019122566A3 (enExample) | 2021-12-22 |
| MX386181B (es) | 2025-03-18 |
| US11339181B2 (en) | 2022-05-24 |
| IL267393B2 (en) | 2023-07-01 |
| TW201829423A (zh) | 2018-08-16 |
| WO2018117153A1 (en) | 2018-06-28 |
| EP3559003A1 (en) | 2019-10-30 |
| JP2020502224A (ja) | 2020-01-23 |
| IL267393A (en) | 2019-08-29 |
| ES2926986T3 (es) | 2022-10-31 |
| IL267393B1 (en) | 2023-03-01 |
| AU2017380213A1 (en) | 2019-05-23 |
| TWI822666B (zh) | 2023-11-21 |
| RU2019122566A (ru) | 2021-01-22 |
| KR102788829B1 (ko) | 2025-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017380213B2 (en) | Crystalline forms of a janus kinase inhibitor | |
| KR102090453B1 (ko) | 상피 성장 인자 수용체 키나제 억제제의 염 | |
| AU2019338032A1 (en) | Salts of substituted pyrrolopyrimidine CDK inhibitor, crystal and use thereof | |
| EP4332102A1 (en) | Isoquinolone compound and use thereof | |
| CA3116652A1 (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt | |
| CA2926845C (en) | Salt and crystal forms of plk-4 inhibitor | |
| KR20190086442A (ko) | 피리딘 화합물 | |
| US20250270221A1 (en) | Solid forms of jak inhibitor and process of preparing the same | |
| WO2024042363A1 (en) | Tyk2 inhibitors and uses thereof | |
| EP2975035B1 (en) | Salt of pyrrolidin-3-yl acetic acid derivative and crystals thereof | |
| RU2838992C2 (ru) | Кристаллические формы ингибитора янус-киназы | |
| CN112543634A (zh) | Ebna1抑制剂晶体形式及其制备和使用方法 | |
| CN110903291B (zh) | 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的盐、盐的晶型及制备方法 | |
| BR122024025362A2 (pt) | Formas cristalinas de um inibidor de janus cinase, composição farmacêutica compreendendo as ditas formas cristalinas, seu uso e métodos de medição | |
| HK40050819A (en) | Ebna1 inhibitor crystalline forms, and methods of preparing and using same | |
| WO2023008470A1 (ja) | 縮環アミン誘導体 | |
| EA052157B1 (ru) | Фармацевтическая композиция для перорального введения, содержащая производное аминопиримидина или его соль | |
| HK40057216B (en) | Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor | |
| HK40057216A (en) | Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20221219 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20241015 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T13-T101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241022 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241022 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241206 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241206 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241206 |
|
| C11 | Application revival requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED Effective date: 20251014 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251014 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251208 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251208 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED Effective date: 20260211 |
|
| R13 | Change to the name of applicant or owner recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260220 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260220 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260409 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260514 |
|
| C13 | Application revived following an application revival request |
Free format text: ST27 STATUS EVENT CODE: A-6-2-C10-C13-C102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUIREMENTS DEEMED COMPLIANT FOR ALL ABANDONMENT REASONS Effective date: 20260519 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260519 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260519 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260526 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260526 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260629 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260629 |